Axogen Inc (AXGN)vsBoston Scientific Corp (BSX)
AXGN
Axogen Inc
$42.16
+0.74%
HEALTHCARE · Cap: $2.54B
BSX
Boston Scientific Corp
$42.98
-0.28%
HEALTHCARE · Cap: $62.29B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 8259% more annual revenue ($21.00B vs $251.17M). BSX leads profitability with a 17.5% profit margin vs -13.4%. BSX appears more attractively valued with a PEG of 0.60. BSX earns a higher WallStSmart Score of 72/100 (B).
AXGN
Avoid30
out of 100
Grade: F
BSX
Strong Buy72
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AXGN.
Margin of Safety
-10.0%
Fair Value
$39.07
Current Price
$42.98
$3.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Revenue surging 23.1% year-over-year
Large-cap with strong market position
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 22.9%
Generating 1.3B in free cash flow
Areas to Watch
Trading at 8.8x book value
0.0% earnings growth
Weak financial health signals
Expensive relative to growth rate
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AXGN
The strongest argument for AXGN centers on Debt/Equity, Revenue Growth. Revenue growth of 23.1% demonstrates continued momentum.
Bull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, P/E Ratio. Profitability is solid with margins at 17.5% and operating margin at 22.9%. PEG of 0.60 suggests the stock is reasonably priced for its growth.
Bear Case : AXGN
The primary concerns for AXGN are Price/Book, EPS Growth, Piotroski F-Score.
Bear Case : BSX
The primary concerns for BSX are Altman Z-Score.
Key Dynamics to Monitor
AXGN profiles as a growth stock while BSX is a mature play — different risk/reward profiles.
AXGN carries more volatility with a beta of 1.16 — expect wider price swings.
AXGN is growing revenue faster at 23.1% — sustainability is the question.
BSX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (72/100 vs 30/100), backed by strong 17.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Axogen Inc
HEALTHCARE · MEDICAL DEVICES · USA
AxoGen, Inc., develops and markets surgical solutions for physical damage or transection of peripheral nerves. The company is headquartered in Alachua, Florida.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?